Sino Biopharmaceutica Net Income vs. Revenue
| SBHMY Stock | USD 9.05 0.00 0.00% |
For Sino Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sino Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sino Biopharmaceutical Ltd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sino Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sino Biopharmaceutical Ltd over time as well as its relative position and ranking within its peers.
Sino |
Sino Biopharmaceutical Revenue vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sino Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Sino Biopharmaceutica value to that of its competitors to determine the firm's financial worth. Sino Biopharmaceutical Ltd is currently regarded as top stock in net income category among its peers. It also is currently regarded number one company in revenue category among its peers totaling about 1.84 of Revenue per Net Income. Comparative valuation analysis is a catch-all model that can be used if you cannot value Sino Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sino Biopharmaceutica's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sino Revenue vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Sino Biopharmaceutica |
| = | 14.61 B |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Sino Biopharmaceutica |
| = | 26.86 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Sino Revenue vs Competition
Sino Biopharmaceutical Ltd is currently regarded number one company in revenue category among its peers. Market size based on revenue of Biotechnology industry is at this time estimated at about 26.98 Billion. Sino Biopharmaceutica totals roughly 26.86 Billion in revenue claiming about 100% of stocks in Biotechnology industry.
Sino Biopharmaceutica Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sino Biopharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sino Biopharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Sino Biopharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Sino Biopharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States.
Sino Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sino Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sino Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sino Biopharmaceutica's important profitability drivers and their relationship over time.
Use Sino Biopharmaceutica in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sino Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sino Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Sino Biopharmaceutica Pair Trading
Sino Biopharmaceutical Ltd Pair Trading Analysis
The ability to find closely correlated positions to Sino Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sino Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sino Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sino Biopharmaceutical Ltd to buy it.
The correlation of Sino Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sino Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sino Biopharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sino Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sino Biopharmaceutica position
In addition to having Sino Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sector ETFs Thematic Idea Now
Sector ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 439 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.